Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis

Table 2 Subgroup analysis for OS

Subgroup	Number of studies	Number of patients	HR(95% CI)	P value	Heterogeneity
Location
China	4	455	2.86 (1.44–5.66)	0.003	I² = 45.1%; P = 0.141
Korea	4	354	0.47 (0.29–0.77)	0.002	I² = 0%; P = 0.836
USA	1	86	2.42 (1.03–5.67)	0.042	/
Norway	1	38	1.08 (0.64–1.81)	0.771	/
Japan	2	1388	1.99 (1.29–3.08)	0.002	I² = 0%; P = 0.557
Cut-off value
≥ 30%	4	1627	2.54 (1.56–4.12)	< 0.001	I² = 37%; P = 0.19
≤ 10%	7	694	0.98 (0.55–1.73)	0.938	I² = 68.7%; P = 0.004
Tumor type
DLBCL	6	1842	1.70 (1.05–2.74)	0.031	I² = 47.2%; P = 0.092
NK/T	3	229	1.07 (0.21–5.59)	0.935	I² = 89.3%; P < 0.001
FL	1	38	1.08 (0.64–1.81)	0.771	/
PCNSL	1	76	0.84 (0.20–3.55)	0.813	/
ATLL	1	136	2.37 (1.15–4.90)	0.020	/
Therapy
Chemotherapy	5	1573	2.16 (0.85–5.49)	0.105	I² = 73.6%; P = 0.004
Chemotherapy+other treatments	7	748	1.12 (0.69–1.84)	0.646	I² = 68.5%; P = 0.004
Sample size
≥ 100	5	1818	1.64 (0.90–3.01)	0.529	I² = 57.8%; P = 0.05
< 100	7	503	1.26 (0.66–2.43)	0.480	I² = 76.8%; P < 0.001
Antibody type
MAB	9	2068	1.17 (0.75–1.83)	0.476	I² = 68.4%; P = 0.001
PAB	3	253	3.23 (0.89–11.74)	0.075	I² = 64%; P = 0.062
Antibody source
Rabbit	10	989	1.52 (0.91–2.55)	0.212	I² = 70.6%; P < 0.001
Mouse	2	1332	0.98 (0.27–3.52)	0.978	I² = 84.5%; P = 0.011

HR hazard ratio, CI confidence interval, DLBCL diffuse large B cell lymphoma, NK/T NK/T cell lymphoma, FL follicular lymphoma, PCNSL primary central nervous system lymphoma, ATLL adult T cell lymphoma/leukemia, MAB monoclonal antibody, PAB polyclonal antibody

ISSN: 1471-2407